🇺🇸 FDA
Pipeline program

SGT-001

GX1001

Phase 2 gene_therapy active

Quick answer

SGT-001 for Duchenne Muscular Dystrophy is a Phase 2 program (gene_therapy) at Solid Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Solid Biosciences
Indication
Duchenne Muscular Dystrophy
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials